atrasentan has been researched along with Kidney Failure, Chronic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW | 1 |
| Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Dey, J; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M | 1 |
| Nangaku, M | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| Batu Demir, D; Cooper, ME | 1 |
| Polakowski, JS; Pollock, DM | 1 |
1 review(s) available for atrasentan and Kidney Failure, Chronic
| Article | Year |
|---|---|
New strategies to tackle diabetic kidney disease.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy | 2016 |
2 trial(s) available for atrasentan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Topics: Aged; Area Under Curve; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome | 2021 |
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Precision Medicine; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Severity of Illness Index | 2018 |
3 other study(ies) available for atrasentan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Light of dawn in Melbourne: SONAR and CREDENCE.
Topics: Atrasentan; Australia; Canagliflozin; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Kidney Failure, Chronic; Nephrology; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protein Precursors; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 1997 |